Study Comparing ZL-1310 to Other Treatments for Relapsed Small Cell Lung Cancer

Inclusion Criteria

• Be 18 years or older, or considered an adult by local standards.
• Have signed a consent form agreeing to participate.
• Have a confirmed diagnosis of small cell lung cancer (SCLC).
• Have received initial treatment with platinum-based chemotherapy and experienced cancer progression during or after this treatment, or have received a second-line treatment called tarlatamab.
• Have measurable cancer according to specific medical criteria.
• Have a history of treated and stable, or untreated and symptom-free, cancer spread to the brain or spinal cord.
• Have good organ and bone marrow function.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 3 months.
• Be willing to undergo a tumor biopsy or provide a previous tumor sample.
• Be willing and able to follow the study procedures for its duration.

Exclusion Criteria

• Have received more than one line of treatment for extensive-stage small cell lung cancer.
• Have previously received a specific type of drug called ADC with topoisomerase 1 inhibitor.
• Have another type of cancer, with some exceptions.
• Have a history or suspicion of lung diseases like interstitial lung disease or pneumonitis.
• Have severe lung problems due to other lung illnesses.
• Have received any cancer treatment within 3 weeks before starting the study treatment.
• Have had prior radiation therapy before starting the study treatment, based on specific criteria.
• Have unresolved side effects from previous cancer treatments, except for hair loss and skin color changes.
• Have a known or active infection.
• Have significant heart disease or a history of blood clots in the arteries within 6 months before starting the study treatment.